Vanguard European Stock Index Fund Institutional Plus USD AccRegister to Unlock Ratings |
Performance History | 31/10/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 2.4 | 17.8 | -4.1 | 13.5 | 5.5 | |
+/-Cat | -1.9 | 2.4 | 4.2 | 1.9 | 1.8 | |
+/-B’mrk | -0.2 | 0.1 | 0.5 | 0.3 | 0.1 | |
Category: Europe Large-Cap Blend Equity | ||||||
Category Benchmark: Morningstar DM Eur TME NR EUR |
Key Stats | ||
NAV 21/11/2024 | USD 162.91 | |
Day Change | 0.61% | |
Morningstar Category™ | Europe Large-Cap Blend Equity | |
ISIN | IE00BFPM9K89 | |
Fund Size (Mil) 21/11/2024 | USD 4033.06 | |
Share Class Size (Mil) 21/11/2024 | USD 79.86 | |
Max Initial Charge | - | |
Ongoing Charge 05/03/2024 | 0.08% |
Investment Objective: Vanguard European Stock Index Fund Institutional Plus USD Acc |
The Fund seeks to provide long-term growth of capital by tracking the performance of the Index. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Not Disclosed 14/09/1998 | ||
Inception Date 19/12/2013 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
MSCI Europe NR USD | Morningstar DM Eur TME NR EUR |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Vanguard European Stock Index Fund Institutional Plus USD Acc | 30/09/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk AS Class B | Healthcare | 3.30 |
ASML Holding NV | Technology | 2.90 |
Nestle SA | Consumer Defensive | 2.30 |
AstraZeneca PLC | Healthcare | 2.10 |
SAP SE | Technology | 2.07 |
Increase Decrease New since last portfolio | ||
Vanguard European Stock Index Fund Institutional Plus USD Acc |